

**ADDENDUM 0382 8 APR 17 P1:20**

**TO THE**

**CITIZEN PETITION**

**OF THE**

**AMERICAN DIETETIC ASSOCIATION, THE OBESITY SOCIETY,  
SHAPING AMERICA'S HEALTH, AND GLAXOSMITHKLINE  
CONSUMER HEALTHCARE**

**REQUESTING**

**THE FOOD AND DRUG ADMINISTRATION**

**TO**

**DETERMINE THAT CLAIMS THAT DIETARY SUPPLEMENTS  
PROMOTE, ASSIST, OR OTHERWISE HELP IN WEIGHT LOSS ARE  
DISEASE CLAIMS UNDER SECTION 403(R)(6) OF THE FEDERAL  
FOOD, DRUG AND COSMETIC ACT**

**APRIL 17, 2008**

**ADDENDUM TO THE CITIZEN PETITION REQUESTING FDA TO  
DETERMINE THAT WEIGHT LOSS CLAIMS ARE DISEASE CLAIMS**

**EXHIBIT BINDER INDEX**

<b><u>TAB</u></b>	<b><u>DOCUMENT</u></b>
1	Ogden CL, et al. Prevalence of overweight and obesity in the United States, 1999-2004. <i>JAMA</i> 2006;295:1549-55.
2	Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Washington, DC: National Institutes of Health, September 1998. (NIH Publication No. 98-4083.)
3	Blackburn G, Fernstrom M, Foreyt J, Frank A, Wolf A. Impact of overweight on morbidity and mortality: report submitted to GlaxoSmithKline Consumer Healthcare. November 1, 2007.
4	Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. <i>Am J Epidemiol</i> 1990;132:501-13.
5	Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. <i>Ann Intern Med</i> 1995;122:481-6.
6	Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes in women. <i>N Engl J Med</i> 2001;345:790-7.
7	Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. <i>Arch Intern Med</i> 2001;161:1581-6.
8	Burke JP, Williams K, Venkat Narayan KM, Leibson C, Haffner SM, Stern MP. A population perspective on diabetes prevention: whom should we target for preventing weight gain? <i>Diabetes Care</i> 2003;26:1999-2004.
9	St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. <i>Diabetes Care</i> 2004;27:2222-8.
10	American Heart Association; American Stroke Association. Heart disease and stroke statistics: 2008 update at-a-glance. Dallas, TX: American Heart Association, 2008.
11	Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE,

TABDOCUMENT

- Hennekens CH. Weight, weight change, and coronary heart disease in women. JAMA 1995;273:461-5.
- 12 Rimm EB, Stampfer JM, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older U.S. men. Am J Epidemiol 1995;141:1117-27.
- 13 Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001;9(Suppl 4):326S-34S.
- 14 Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998;97:2099-100.
- 15 Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: impact on cardiovascular disease. Circulation 1998;98:1472-6.
- 16 Wilson PWF, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72.
- 17 Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79:379-84.
- 18 Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jiminez F. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666-78.
- 19 Baker JL, Olsen LW, Sorensen, TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007;357:2329-37.
- 20 Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565-74.
- 21 Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature 2004;4:579-91.
- 22 World Cancer Research Fund; American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research, 2007.

<u>TAB</u>	<u>DOCUMENT</u>
23	Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. <i>N Engl J Med</i> 2003;348:1625-38.
24	Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. <i>JAMA</i> 2002;288:1723-7.
25	Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. <i>JAMA</i> 2004;291:2847-50.
26	McTigue KM, Garrett JM, Popkin BM. The natural history of the development of obesity in a cohort of young U.S. adults between 1981 and 1998. <i>Ann Intern Med</i> 2002;136:857-64.
27	Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Wadden TA, Pettinico G, Burton SL. Interaction with physicians among overweight adults in the United States. Poster session presented at: NAASO, The Obesity Society 2006 Annual Meeting; October 2006; Boston, MA.  Pillitteri JL, Shiffman S, Rohay JM, Wadden TA, Harkins AM, Burton SL, Pettinico G. Dietary supplement use for weight loss among US adults. Poster session presented at: NAASO, The Obesity Society 2006 Annual Meeting; October 2006; Boston, MA.
	Pillitteri J, Burton S, Shiffman S, Rohay J, Harkins A, Pettinico G. Consumers' use and beliefs about dietary supplements for weight loss. Poster session presented at: 10th International Congress on Obesity; September 2006; Sidney, Australia.
28	Blanck HM, Serdula MK, Gillespie C, et al. Use of nonprescription dietary supplements for weight loss is common among Americans. <i>J Am Diet Assoc</i> 2007;107:441-7.
29	Wilson KM, Klein JD, Sesselberg TS, et al. Use of complementary medicine and dietary supplements among U.S. adolescents. <i>J Adolesc Health</i> 2006;38:385-94.
30	Ashar BH, Rice TN, Sisson SD. Physicians' understanding of the regulation of dietary supplements. <i>Arch Intern Med</i> 2007;167:966-9.

<u>TAB</u>	<u>DOCUMENT</u>
31	Wellness International Network, Ltd. Courtesy Letter (Ltr. 945; June 12, 2007); New Chapter, Inc. Courtesy Letter (Ltr. 888; June 5, 2006); Nutrition 21 Courtesy Letter (Ltr. 882; May 3, 2006); Source Naturals, Inc. Courtesy Letter (Ltr. 619, June 21, 2002).
32	Healing Power, Inc. Courtesy Letter (Ltr. 885; May 23, 2006); USANA Health Sciences, Inc. Courtesy Letter (Ltr. 879; May 3, 2006); Anabolic Laboratories, Inc. Courtesy Letter (Ltr. 782; September 29, 2004).
33	New Chapter, Inc. Courtesy Letter (Ltr. 935; April 3, 2007); New Century Company Courtesy Letter (Ltr. 873, Mar. 29, 2006); KNature Corp. Courtesy Letter (Ltr. 807; February 4, 2005); NOW Foods Courtesy Letter (Ltr. 799; December 6, 2004); Michael's Naturopathic Programs Courtesy Letter (Ltr. 730; October 15, 2003).
34	Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. <i>J Am Diet Assoc</i> 2005;105(5 Suppl 1):S80-6.
35	Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. <i>Am Fam Physician</i> 2004;70:1731-8.
36	Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. <i>Am J Clin Nutr</i> 2004;79:529-36.
37	Lenz TL, Hamilton WR. Supplemental products used for weight loss. <i>J Am Pharm Assoc</i> 2004;44:59-67.
38	DeBusk RM. A critical review of the literature on weight loss supplements. <i>Integr Med Consult</i> 2001;3:30-1.
39	Sharpe PA, Granner ML, Conway JM, et al. Availability of weight-loss supplements: results of an audit of retail outlets in a Southeastern city. <i>J Am Diet Assoc</i> 2006;106:2045-51.
40	Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. <i>Expert Biol Med</i> 2004;229:698-704.
41	Bent S, et al. Safety and efficacy of citrus aurantium for weight loss. <i>Am J Cardiol</i> 2004;94:1359-61.

<u>TAB</u>	<u>DOCUMENT</u>
42	Hess AM, Sullivan DL. Potential for toxicity with use of bitter orange and guarana for weight loss. <i>Ann Pharmacother</i> 2005;39:574-5.
43	Bouchard NC, et al. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. <i>Mayo Clin Proc</i> 2005;80:541-5.
44	Nykamp D, Fackih MN, Comptom AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. <i>Ann Pharmacother</i> 2004;38:812-6.
45	Bahadori B, Wallner S, Schneider H, Wascher TC, Toplak H. [Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet]. <i>Acta Med Austriaca</i> 1997;24:185-7. German.
46	Pasman WJ, Westerterp-Plantenga MS, Saris WHM. The effectiveness of long-term supplementation of carbohydrate, chromium, fibre and caffeine on weight maintenance. <i>Int J Obes</i> 1997;21:1143-51.
47	Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. <i>Diabetes Obes Metab</i> 1999;1:331-7.
48	Lukaski HC, et al. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. <i>Nutrition</i> 2007;23:187-95.
49	Pittler MH, Ernst E. Guar gum for body weight reduction, meta-analysis of randomized trials. <i>Am J Med</i> 2001;110:724-30.
50	Lee RL, Balick MJ. Indigenous use of <i>Hoodia gordonii</i> and appetite suppression. <i>Explore</i> 2007;3:404-6.
51	Joyal SV. A perspective on the current strategies for the treatment of obesity. <i>Current Drug Targets – CNA &amp; Neurological Disorders</i> 2004;3:341-56.
52	Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. <i>Garcinia cambogia</i> (hydroxycitric acid) as a potential antiobesity agent. <i>JAMA</i> 1998;280:1596-600.
53	Rothacker DQ, Waitman BE. Effectiveness of a <i>Garcinia cambogia</i> and natural caffeine combination in weight loss: a double-blind, placebo-controlled pilot study. <i>Int J Obes</i> 1997;21(Suppl 2):53.

**TAB****DOCUMENT**

- 54 Antonio J, Colker CM, Tornia GC, Shi Q, Brink W, Kalman D. Effects of a standardized guggulsterone phosphate supplement on body composition in overweight adults: a pilot study. *Curr Ther Res* 1999;60:220-7.
- 55 Thom E. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. *J Int Med Res* 2000;28:229-33.
- 56 Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. *J Nutr* 2000;130:2943-8.
- 57 Risérus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of metabolic syndrome: a randomized controlled trial. *Int J Obes* 2001;25:1129-35.
- 58 Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans: metabolic effects. *Lipids* 2001;36:773-81.
- 59 Risérus U, Smedman A, et al. Metabolic effects of conjugated linoleic acid in humans: the Swedish experience. *Am J Clin Nutr* 2004;79:1146S-8S.
- 60 Larsen TM, Toubro S, Astrup A. Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies. *J Lipid Res* 2003;44:2234-41.
- 61 Kalman D, Colker CM, Wilets I, Roufs JB, Antonio J. The effects of pyruvate supplementation on body composition in overweight individuals. *Nutrition* 1999;15:337-40.
- 62 Kalman D, Colker CM, Stark R, Minsch A, Wilets I, Antonio J. Effects of pyruvate supplementation on body composition and mood. *Curr Ther Res* 1998;59:793-802.
- 63 Pittler MH, Abbott NC, et al. Randomized, double blind trial of chitosan for body weight reduction. *Eur J Clin Nutr* 1999;53:379-81.
- 64 Mhurchu CN, Poppitt SD, et al. The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. *Int J Obes* 2004;28:1149-56.
- 65 Ho SC, Tai ES, et al. In the absence of dietary surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. *Singapore Med J* 2001;42:6-10.

<u>TAB</u>	<u>DOCUMENT</u>
66	Gades MD, Stern JS. Chitosan supplementation and fat absorption in men and women. J Am Diet Assoc 2005;105:72-7.
67	Pittler MH, Schmidt K, Ernst E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obesity Reviews 2005;6:93-111.